# AJOVY® Formally Included in China's National Reimbursement Drug List 2026 - Link: https://www.thailand-business-news.com/pr-news/ajovy-formally-included-in-chinas-national-reimbursement-drug-list-2026 - Published: 2026-11-14T20:51:00+07:00 - Author: PR Newswire SHANGHAI, Nov. 14, 2026 /PRNewswire/ — On November 14, NeuroGen announced that it’s in-licensed innovative drug **AJOVY^(®)** (fremanezumab injection) from TEVA has been successfully listed on China’s National Reimbursement Drug List (NRDL) following the latest round of national price negotiations^(1). Marking a breakthrough as the first CGRP inhibitor covered by national insurance, **AJOVY^(® )**achieved same- year NRDL inclusion after its initial approval in June—a milestone expected to dramatically improve patient access and relieve the long-term financial burden for patients in China living with migraine. ◦ **AJOVY^(®)** is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand^(2) ◦ Among currently marketed anti-CGRP monoclonal antibodies, fremanezumab injection is the only subcutaneous therapy offering both monthly and quarterly dosing options ^(3) ◦ Supported by multiple pivotal clinical studies, fremanezumab injection has proven effective and safe in adult migraine prevention, serving as the sole CGRP mAb to evaluate efficacy through a standalone Phase III trial in Chinese patients ^(4,5,6,7) **Sean Chen, Chief Executive Officer of NeuroGen Pharma, **stated: "**Fremanezumab Injection’s inclusion in the NRDL** within the same year of approval reflects strong policy support for clinically needed innovation. As a key in-licensed product accelerating our local delivery of global innovations, its enhanced accessibility will bring breakthrough clinical benefits and financial relief to migraine patients. NeuroGen is fully committed to securing a steady nationwide supply, bringing cutting-edge innovation to benefit more families faster." Migraine is a common chronic neurological disease. Evidence suggests that approximately 100 million individuals in China live with migraine^(8), with a 9.3% annual prevalence rate among adults aged 18 to 65^(9). Characterized by a substantial disease burden and recurrent attacks, migraine persistently impacts patients’ work productivity, social activities, and overall quality of life^(8). Reducing attack frequency and mitigating its impact on daily life are therefore crucial goals in adult migraine management^(9). **AJOVY^(®)**** in China:** ◦ **2023**– It was approved by the Guangdong Provincial Medical Products Administration, pioneering the "Hong Kong and Macao Medicine and Equipment Connect" policy in the Guangdong-Hong Kong-Macao Greater Bay Area; ◦ **2024**– Fremanezumab met its primary and all secondary endpoints in a China Phase III study, demonstrating efficacy in the Chinese population^(13); ◦ **April 2026**– NeuroGen entered a strategic partnership with Teva, obtaining exclusive commercialization rights in China^(14); ◦ **June 2026**– It was approved by the NMPA for the preventive treatment of migraine in adults^(15); ◦ **November 2026**– It was formally included in the China NRDL^(1). CGRP-targeted monoclonal antibodies, representing a core novel mechanism in preventive migraine therapy, are explicitly recommended across multiple domestic and international landmark guidelines. Key endorsees include the _Calcitonin gene-related peptide- targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update^(11)_ the _Chinese Guidelines for the Diagnosis and Treatment of Migraine^(9)_, the _Chinese practice guidelines for diagnosis and treatment of migraine^(10) _and the _Chinese expert consensus on the diagnosis and treatment of medication overuse headache^(12)_. **About AJOVY^(®) (Fremanezumab Injection)** AJOVY is an innovative migraine treatment developed by Teva Pharmaceuticals and it offers both monthly (225mg) and quarterly (675mg) subcutaneous dosing options ^(16). Among currently marketed anti-CGRP monoclonal antibodies, AJOVY is the only therapy offering these two dosing regimens^(3). The quarterly dosing option significantly reduces injection frequency, helping patients adhere to treatment and sustain long- term control of migraine attacks. The efficacy and safety of AJOVY are supported by multiple clinical studies. A China Phase III study in adult migraine demonstrated a significant reduction in monthly migraine days with a favorable safety profile ^(4). It was first approved in adults by the U.S. Food and Drug Administration (FDA) in 2018^(3) and by the European Medicines Agency (EMA) in 2019^(3). In 2025, AJOVY was approved by the FDA for single-dose injection use in children and adolescents aged 6–17 years with episodic migraine weighing 45 kg or more, becoming the world’s first and only CGRP antagonist approved for both pediatric episodic migraine prevention and adult migraine prevention^(3). **About NeuroGen ** NeuroGen Pharma was established in 2024 when Mubadala Investment Company and C-Bridge Capital jointly carved out CNS and Allergy originator portfolios of UCB and its Zhuhai Manufacturing site in China. Leveraging its end-to-end capabilities covering R&D, manufacturing, and commercialization, NeuroGen focuses on addressing unmet clinical needs in neurology and allergy, with synergistic expansions into pain management. The company is building a scalable, growth-oriented biopharmaceutical platform dedicated to transforming care for better patient outcomes. Visit us at [www.neurogen.com.cn](https://www.neurogen.com.cn/) to learn more. | 参考文献： | | 1.  国家基本医疗保险、工伤保险和生育保险药品目录（2026年） | | 2.  Mitsikostas D, et al. Pain Manag. 2025 Nov;15(11):791-800. | | 3.  艾久维_在华获批，灵活给药为偏头痛长期管理带来新选择 https://mp.weixin.qq.com/s/4dmPgbvVKRPhzPhuBQZZ_w | | 4.  Yu S, et al. Cephalalgia, 2026, 46(8): 1–13. | | 5.  Silberstein SD, et al. N Engl J Med. 2017 Nov 30;377(22):2113-2122. | | 6.  Dodick DW, et al. JAMA. 2018 May 15;319(19):1999-2008. | | 7.  Ferrari MD, et al. Lancet. 2019 Sep 21;394(10203):1030-1040. | | 8.  Wang YX, et al. J Headache Pain. 2025 May 6;26(1):104. | | 9.  中国医师协会神经内科医师分会, 等. 中国疼痛医学杂志, 2022,28(12)881-898. | | 10.  中华医学会神经病学分会, 等. 中华神经科杂志,2023,56(6):591-613. | | 11.  Charles AC, et al.  Headache, 2024, 64(4): 333-341. | | 12.  中华医学会神经病学分会头痛协作组, 等. 中华神经科杂志，2026, 59 (1): 18–33. | | 13.  Efficacy Outcomes From a Phase 3, Randomised, Double–Blind, Placebo–Controlled Study of Fremanezumab for the Preventive Treatment of Migraine in Chinese Adults[C]. 20th Migraine Trust International Symposium, London, UK, 2024. | | 14.  神基制药官网公告. | | 15.  2026年06月08日药品批准证明文件送达信息. | | 16.  夫瑞奈珠单抗注射液说明书. 2026年06月03日. |   --- | This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. | --- **Read the original article :** [AJOVY® Formally Included in China's National Reimbursement Drug List 2026 ](https://en.prnasia.com/story/archive/5097936_AE97936_0?rand=184833)